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Thioredoxin interacting protein (TXNIP), which has a tumor-suppressive function, is 
under-expressed in some human cancers. The function of TXNIP in vivo in carcinogenesis is 
not fully understood. Here, we show TXNIP to be down-regulated in human bladder cancer 
according to grade and stage and also that loss of TXNIP expression facilitates bladder 
carcinogenesis using a mouse bladder cancer model. N-butyl-N-(4-hydroxybutyl) nitrosamine 
(BBN)-induced bladder cancer was found in 100% of Txnip knock-out (KO) mice at week 8 
of 0.025% BBN administration, but in only 22% of wild-type (WT) mice at the same point. 
Among growth stimulators, phospho-ERK (pERK) expression was stronger during bladder 
carcinogenesis in Txnip-KO mice than in WT mice. We then evaluated TXNIP’s effects on 
ERK activation through various growth stimulators and their receptors. Over-expression of 
TXNIP in human bladder cancer cells attenuated pERK expression upon stimulation with 
stromal cell-derived factor-1 (SDF-1), but not with EGF or IGF-1. In Txnip-KO mice, 
immunohistochemical analysis showed enhanced expression of CXCR4, the receptor of 
SDF-1, and of pERK in urothelial cells during BBN-induced bladder carcinogenesis. Finally, 
subcutaneous injection of CXCR4 antagonist, TF14016, attenuated pERK in urothelial cells 
and suppressed bladder carcinogenesis. These data indicate that TXNIP negatively regulates 
bladder carcinogenesis by attenuating SDF-1-CXCR4-induced ERK activation. This signal 
transduction pathway can be a potent target in preventing or treating bladder cancer.  
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Introduction 
Bladder cancer is the fifth most common malignancy in the Western society; more than 
70,000 new cases of bladder cancer are diagnosed every year in the United States (1). About 
70% of patients present with non-muscle invasive bladder tumors, and the remaining 30% 
present with high-grade invasive tumors at initial diagnosis. Low-grade non-muscle invasive 
bladder tumors can be treated by transurethral resection with an excellent patient prognosis. 
But high-grade non-muscle invasive bladder cancer, including carcinoma in situ (CIS), tends 
to invade the muscle layer and metastasize (2), which causes high mortality or severe 
impairment of quality of life, even if it is cured. The development of bladder tumors is 
thought to be a multifactorial process and to occur as a direct consequence of the mutagenic 
actions of chemical or physical carcinogens, such as tobacco smoking. The precise 
mechanisms underlying carcinogen-induced bladder carcinogenesis have not yet been 
clarified. To approach this question, N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced 
mouse bladder carcinoma model has been used widely since the 1970s. One feature of this 
mouse model is that BBN can induce high-grade non-muscle invasive bladder cancer, 
followed by muscle invasive bladder cancer, in almost all subject animals (3).  
In general, epithelial cells receive oncogenic growth signals that originate in the 
extracellular environment in response to carcinogenic stimuli (4). Aberrant activation of 
mitogen-activated protein kinase (MAPK) cascades, such as c-Jun N-terminal kinase (JNK) 
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and extracellular signal-regulated kinase (ERK), and oncogenic signals involving AKT have 
been shown to lead to excessive cell growth and division in early-stage carcinogenesis (5). 
Specifically, up-regulation of oncogenic signaling genes involved in the Ras-Raf-MAPK 
cascade have been reported in the advanced stages of BBN-induced bladder cancer (6). The 
MAPKs are activated by receptor signaling pathways, including receptor tyrosine kinases 
(such as epidermal growth factor receptor [EGFR] and type 1 insulin-like growth factor 
receptor [IGF-1R]). In addition, seven-transmembrane receptors (7TMRs) have been also 
reported to activate MAPK signaling. Among the 7TMRs leading to activation of MAPKs, 
chemokine receptor CXCR4, which is activated exclusively by its ligand stromal cell-derived 
factor 1 (SDF-1), is up-regulated in many kinds of cancers, including bladder carcinoma. 
Indeed, CXCR4 was identified as the only chemokine receptor up-regulated in 
muscle-invasive bladder cancer by screening expression levels of all chemokine receptors in 
normal urothelium and bladder cancer. (7). It is also up-regulated in high-grade non-muscle 
invasive bladder cancers including CIS (8), although the role of SDF-1-CXCR4 signaling in 
bladder carcinogenesis remains unclear. 
Thioredoxin interacting protein (TXNIP), also known as thioredoxin binding protein-2 
(TBP-2) or vitamin D3 up-regulated protein 1 (VDUP1), is a multi-functional protein. It binds 
to and inhibits thioredoxin 1 (TRX1), a major redox-regulating molecule, and also plays roles 
in the development of NK cells, glucose metabolism, cell cycle arrest, and inflammatory 
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signal regulation (9–11). Regarding the relationship between TXNIP and cancer, TXNIP 
expression is down-regulated in gastric, breast, and colorectal cancers (12–15). However, its 
expression level and role in bladder cancer have not been reported. Moreover, although 
several growth suppressive mechanisms of TXNIP have been extensively studied in vitro, the 
tumor suppressive functions have not been fully elucidated in vivo.  
We previously analyzed comprehensive gene expression profiles in recurrent bladder 
cancer (16,17), and we have found that TXNIP is suppressed in bladder cancer. In the present 
study, we show that TXNIP is down-regulated according to grade and stage in human bladder 
cancers, and that deletion of Txnip accelerates BBN-induced bladder carcinogenesis in vivo. 
Additionally, we show that restoration of TXNIP attenuates ERK activation upon SDF-1 
stimulation. Furthermore, pharmacological blockade of SDF-1-CXCR4 signaling inhibits in 
vivo BBN-induced bladder carcinogenesis accompanied with marked down-regulation of 
ERK. Here, we show the significant role of TXNIP on SDF-1-CXCR4-ERK signaling 
pathway in the molecular mechanisms underlying carcinogen-induced bladder carcinogenesis. 
 
Materials and methods 
Quantitative RT-PCR 
Total RNA was extracted using an RNeasy Mini kit (QIAGEN, Germany) from cultured cells 
or whole bladders and reverse-transcribed into cDNA using the First-Strand cDNA Synthesis 
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Kit (GE Healthcare, Piscataway, NJ). Following primers were used in PCR reactions: human 
GAPDH (forward 5′-GAAGGTGAAGGTCGGAGTC-3′ and 
reverse 5′-GAAGATGGTGATGGGATTTC-3′), human TXNIP 
(forward 5′-ATGGTGATGTTCAAGAAGATCAAG-3′ and 
reverse 5′-CTCAGGGGCATACATAAAGA-3′), mouse Gapdh 
(forward 5′-ACCACAGTCCATGCCATCAC-3′ and 
reverse 5′-TCCACCACCCTGTTGCTGTA-3′), mouse Txnip 
(forward 5′-TCTCCTAGAAGAGCAGCCTACAGG-3′ and 
reverse 5′-CTCGAAGCCGAACTTGTACTCATA-3′). The real time PCR reaction was 
performed using the 7300 Real-Time PCR System and RT-PCR reagents (Power SYBR 
Green PCR Master Mix, Applied Biosystems, Tokyo, Japan) according to the manufacturer’s 
protocol. The PCR reactions were done in triplicate; three independent experiments were 
performed using different sets of samples. Data were normalized relative to the expression 
level of GAPDH genes. Data in each group were compared with those in another group by 
post hoc test protected least significant difference (Fisher’s PLSD); boxplot graphs were 
drawn using commercially available software. 
Cell culture, stable transfectants, and stimulation by SDF-1α, EGF or IGF-1 
Human bladder cancer cell lines: EJ, HT1376, J82, T24, KK47, RT112, RT4, 253J, and 
TCCSUP were used. The cells were cultured in RPMI 1640 media supplemented with 10% 
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fetal bovine serum (FBS). Stable 253J and TCCSUP transfectants over-expressing TXNIP 
were generated as described previously (18) with some modification. The cells were 
transfected with either pCMV-Tag2b control plasmid or pCMV-Tag2b containing the 
HA-tagged TXNIP gene (HA-TXNIP) using Lipofectamine 2000 (Life Technologies Inc., 
Grand Island, NY). The expression of Tag2b or HA-TXNIP in the transfectants was 
confirmed by sequencing, RT–PCR, and western blot analysis. CXCR4 agonist SDF-1α was 
synthesized by a standard Fmoc-based solid-phase peptide synthesis. Cells were incubated for 
48 to 72 h in RPMI media supplemented with 1% FBS and subsequently treated with SDF-1α 
(100 ng/ml), EGF (50 ng/ml, eBioscience, San Diego, CA), or IGF-1 (250 ng/ml, Cell 
Sciences, Canton, MA). After 10 or 20 minutes, the cells were collected on ice and analyzed. 
The timeframe analysis of pERK was performed using SDF-1α (100 ng/ml) in RPMI media 
without FBS. 
Human bladder cancer specimens 
Bladder cancer samples (n = 39) were taken by transurethral cold-cup biopsy under direct 
vision. Non-malignant ureteral urothelia were dissected and isolated by submucosal injection 
of normal saline from specimens of patients with kidney cancer (n = 6). Patients’ 
characteristics including age, grade, sex, smoking habits, and recurrence-free survival are 
provided in Table 1. Informed written consent was obtained from each patient before 
examination. 
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Txnip-deficient mouse and mouse bladder cancer model 
The present animal experiment was approved by the Animal Research Committee of Kyoto 
University. Txnip hetero-knockout (+/–) mice were generated from C57B/6 mice and 
provided by the Institute for Viral Research, Kyoto University (19). The mice were housed in 
a specific pathogen-free room. Six- to eight-week-old Txnip (–/–) knock-out (KO) mice and 
wild-type (+/+, WT) mice were given drinking water with or without 0.025% BBN (Tokyo 
Kasei Kogyo, Tokyo, Japan). In histopathological analysis, bladders were harvested at 
baseline and after 4, 8, 12, 16, 20, or 24 weeks of treatment (n = 5, 5, 9, 7, 12, 5, or 4 [WT 
mice]; n = 5, 5, 7, 6, 7, 5, or 3 [Txnip-KO mice], respectively). Messenger RNA and total 
protein was extracted from the excised bladders by mechanically scraping the urothelium and 
submucosa. For histological examinations, bladders were fixed in 10% buffered formalin. The 
histopathological diagnosis of the bladder cancer was provided by an experienced pathologist 
(H. K.) (The 2004 WHO Classification of Bladder Tumors). 
Western blot analysis 
Total cellular proteins were extracted by disrupting the cells or homogenizing the whole 
bladders in RIPA buffer. Total cellular protein extracts from cultured cells, mouse bladder 
tissues, and human bladder urothelium were analyzed by SDS-PAGE. Proteins were 
transferred to a PVDF membrane, blocked with 1% non-fat dry milk, and incubated with 
antibodies for the following proteins: HA (Covance Japan, Tokyo, Japan), CXCR4, β-actin 
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(Abcam, Cambridge, UK), VDUP-1, SDF-1 (Santa Cruz, CA), AKT, phospho-AKT (pAKT, 
ser473), JNK, phospho-JNK (pJNK, Thr183/Tyr185), ERK, pERK (Cell Signaling 
Technology Japan, Tokyo, Japan). Stained bands were detected using an ECL-advanced 
system (GE Healthcare, UK) and a LAS 4000 Mini analyzer and ImageReader software 
(Fujifilm, Tokyo, Japan). Densitometric scans of the stained bands were performed with 
ImageJ software (http://rsbweb.nih.gov/ij/). Data were normalized relative to the baseline 
value in each group. The differences in densitometric values for pERK, pAKT, and pJNK 
between WT and Txnip-KO mice were determined by the Mann-Whitney U test. 
Immunohistochemistry of mouse bladder cancer 
After BBN treatment, mouse bladders were inflated and fixed in 10% formalin. Mice without 
BBN treatment were used as negative controls. Human bladder cancer specimens obtained by 
transurethral cold-cup biopsy were fixed in 10% formalin overnight. The tissues were 
embedded in paraffin and were stained with hematoxylin and eosin in accordance with 
standard procedures. The formalin-fixed and paraffin-embedded bladders were stained as 
described previously (8) with antibodies for VDUP1 (1:200 dilution) or pERK (1:100 
dilution). The specificity of the staining was confirmed using the corresponding rabbit or 
mouse IgG as negative controls for primary antibodies. Each tissue sample was observed by 
an eclipse E1000 microscope (Nikon, Tokyo, Japan). 
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Treatment with CXCR4 antagonist TF14016 
A potent CXCR4 antagonist, 4F-benzoyl-TN14003 (TF14016), was synthesized as described 
previously (20). TF14016 was dissolved with sterile water. TF14016 (7.5 mg/kg) was injected 
subcutaneously into nine each wild-type and Txnip-KO mice, every other day, in conjunction 
with 0.025% BBN administration. After 12 weeks of BBN administration, bladders were 
harvested 30 minutes after injection of TF14016 and analyzed using immunohistochemistry 
or western blot analysis. 
 
Results 
Txnip expression is down-regulated in human bladder cancers and in the BBN-induced 
bladder cancer model. 
Expression of TXNIP mRNA in human bladder cancers and bladder cancer cell lines was 
analyzed by quantitative RT-PCR. As shown in Figure 1A, TXNIP mRNA expression was not 
evident in all seven bladder cancer cell lines examined, and significantly decreased in human 
bladder cancers (n = 39) compared to normal urothelium (n = 6) (P < 0.0001). Its expression 
correspondingly decreased according to the grade and stage of the cancer (P = 0.026). 
Next, the expression levels of Txnip mRNA were analyzed in BBN-induced mouse 
bladder cancers. Under our experimental condition, CIS started to develop after 8 weeks of 
BBN administration, and lesions were identified in 86% (6 out of 7) of the mice after 12 
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weeks of BBN administration. Sub-mucosal invasion (pathological T1 or more) was identified 
in all mice (n = 5) at 20 weeks of BBN administration (Figure 1B).Over the course of the 
BBN-induced bladder carcinogenesis, Txnip expression declined time-dependently and was 
reduced to about 24%, in average, of the baseline level at 20 weeks of BBN administration 
(Figure 1C). Interestingly, a 37% decrease in Txnip expression was observed at 4 weeks of 
BBN administration, at which no malignant changes were identified histologically. These data 
indicated that the expression of TXNIP gene was suppressed in the course of human and 
mouse bladder carcinogenesis.  
Knock-out of Txnip accelerates BBN-induced bladder carcinogenesis 
To determine whether the decreased expression of Txnip contributes to the development of 
bladder cancer, the prevalence of bladder cancer in Txnip-KO mice was compared with that in 
WT mice, using the BBN-induced bladder carcinogenesis model. Bladder cancer was 
pathologically identified in 60% (3 out of 5) and 100% (7 out of 7) of the Txnip-KO mice at 4 
and 8 weeks of BBN administration, respectively, whereas it was identified in none of 5 and 
only 22% (2 out of 9) of the WT mice at 4 and 8 weeks, respectively (Figures 2A and B). 
When focusing on high-grade CIS, Txnip-KO mice developed this type of bladder cancers 
about 4 weeks earlier than WT mice (Figure 2C). Moreover, invasive bladder cancer (pT1 or 
more) and/or squamous cell carcinoma (SCC), which have characteristic histological features 
to advanced BBN-induced mouse bladder cancers, were observed also about 4 weeks earlier 
13 
in the Txnip-KO mice than in the WT mice (Figure 2D). Thus, knocking-out Txnip accelerated 
BBN-induced bladder carcinogenesis, suggesting that TXNIP plays a suppressive role for 
bladder carcinogenesis. Although bladder carcinogenesis in WT mice is delayed, it is not 
prevented and is similar to the carcinogenesis in WT mice at 16-20 weeks of BBN treatment. 
This is likely because by that time TXNIP levels were similar in the two groups as shown in 
Figure 2E. TXNIP level in bladder urothelium was down-regulated at 12 and 20 weeks of 
BBN treatment compared to baseline in WT mice (n=3 in each group, Figures 2E). 
Phosphorylation of ERK is enhanced in Txnip-KO mouse bladders during BBN-induced 
bladder carcinogenesis 
To investigate the molecular mechanisms underlying bladder carcinogenesis in Txnip-KO 
mice, the activation levels of oncogenic growth-stimulatory signals were analyzed during 
BBN-induced bladder carcinogenesis in the WT and Txnip-KO mice. The phosphorylation 
levels of AKT, JNK, and ERK were up-regulated at 8 weeks compared to baseline (0 week) in 
both WT and Txnip-KO mice (n = 3 in each group, Figure 3A). Among them, upregulation of 
pERK was about 4-fold enhanced in Txnip-KO mice compared to WT mice at 8 weeks of 
bladder carcinogenesis (P < 0.05), whereas there were no obvious differences in the 
up-regulation of pAKT and pJNK between Txnip-KO and WT mice. Immunohistochemical 
analysis demonstrated that the staining for pERK was enhanced in urothelial cells after 8 
weeks of BBN administration in Txnip-KO mice (Figure 3B). Thus, loss of Txnip resulted in 
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enhanced activation of ERK in bladder urothelium as well as accelerated BBN-induced 
bladder carcinogenesis. 
Overexpression of TXNIP attenuated SDF-1/CXCR4 induced phosphorylation of ERK in 
human bladder cancer cells 
To investigate the impact of TXNIP on ERK activation induced by various growth 
stimulations, such as EGF, IGF-1 or SDF-1, three stable transfectants with HA-tagged TXNIP  
were established from 253J and TCCSUP bladder cancer cell lines (253J-HA-TXNIP-1, 2, 
and TCCSUP-HA-TXNIP). Western blot analysis revealed that phosphorylation levels of 
ERK upon SDF-1 stimulation was lower in 253J-HA-TXNIP-1, -2, and TCCSUP-HA-TXNIP 
than in control cell lines (Figures 4A, B, and S1). On the other hand, there were no differences 
in pERK upon EGF or IGF-1 stimulation between 253J-HA-TXNIP-2 and control cells 
(Figure 4C). Similar results were observed in the other two stable transfectants 
(253J-HA-TXNIP-1 and TCCSUP-HA-TXNIP) upon EGF or IGF-1 stimulation (data not 
shown). There were also no differences in the expression levels of corresponding receptors, 
including EGFR, IGFR, CXCR4, phospho-EGFR, or phospho-IGF-1R (data not shown). 
These results indicate that overexpression of TXNIP attenuates SDF-1-CXCR4-induced 
activation of ERK exclusively. 
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CXCR4 antagonist TF14016 suppresses pERK and BBN-induced carcinogenesis in 
Txnip-KO mice 
The expression status of SDF-1, CXCR4, ERK and pERK were assessed in BBN-induced 
bladder carcinogenesis. SDF-1 and ERK were constantly expressed until 8 weeks of BBN 
administration, whereas CXCR4 was gradually up-regulated in the course of bladder 
carcinogenesis in the WT mice. When Txnip-KO mice were compared with WT mice, there 
were no obvious differences in the expression of SDF-1 and CXCR4. On the other hand, the 
expression of pERK was more enhanced in Txnip-KO mice than in the WT mice (Figure 5A).  
To assess the impact of activation of ERK induced by SDF-1-CXCR4 stimulation on 
enhancement of bladder carcinogenesis in Txnip-KO mice, SDF-1-CXCR4 signaling was 
blocked by a specific CXCR4 antagonist TF14016 in both WT mice and Txnip-KO mice. 
TF14016 was injected subcutaneously into WT mice and Txnip-KO mice every other day for 
12 weeks during BBN administration. No significant adverse effects, including weight loss, 
were observed due to TF14016. Western blot analysis demonstrated that TF14016 markedly 
attenuated pERK in the mouse bladder of both groups to the similar level after 12 weeks of 
BBN consumption (Figure 5B). Pathological examination revealed that the prevalence of 
malignant bladder lesion was remarkably lower in TF14016-treated WT mice and Txnip-KO 




The present study shows novel findings that expression of Txnip mRNA is suppressed in 
human bladder cancers and in a mouse model of BBN-induced bladder carcinogenesis. 
Moreover, we have clearly demonstrated that loss of Txnip facilitates BBN-induced mouse 
bladder carcinogenesis using Txnip-KO mice (Figure 6). In general, a tumor suppressor gene 
is defined as a gene whose partial or complete inactivation leads to an increased likelihood of 
cancer development (4). Txnip is thought to be a tumor suppressor gene based on 
observational evidence of suppressed expression in cancer tissues from various origins (12–15) 
and functional verification using cultured cancer cells in in vitro experimental series (9–11). 
Reportedly, Txnip-deficient mice are also predisposed to renal (21) and hepatocellular (22,23) 
carcinomas. Our data, which indicates that TXNIP functions as a tumor suppressor in 
urothelium, is consistent with its decreased expression in several kinds of cancers. 
We have investigated in vivo functional consequences of TXNIP loss using a 
BBN-induced bladder carcinogenesis model in the Txnip-KO mice. In general, carcinogenic 
stimuli, such as BBN, boost oncogenic growth-stimulatory signals, leading to excessive cell 
growth and division at the early stage of carcinogenesis (5). Therefore, we investigated ERK, 
JNK and AKT signaling as major growth-stimulatory signals, and found that ERK was more 
active in Txnip-KO mice than in WT mice. Aberrant activation of ERK, a second messenger 
involved in an important oncogenic signal transduction pathway, is reportedly associated with 
17 
bladder carcinogenesis, among other cancers. On the other hand, some possible mechanisms 
of TXNIP have been listed in tumor suppression. A previous in vitro study reported that 
TXNIP decreases cell proliferation by restricting cell cycle progression; TXNIP deficiency 
reduced expression of p27, a cyclin-dependent kinase inhibitor (24). Alteration of redox status 
has been also proposed as a mechanism of tumor suppression, since TXNIP inhibit the 
activity of TRX1. However, under the conditions we used to induce bladder carcinogenesis, 
we could not find obvious differences in the expression of TRX1, cell-cycle related genes 
including p27, and the status of redox (8-hydroxy-2′-deoxyguanosine [8-OHdG]) between 
Txnip-KO mice and WT mice (data not shown). Collectively, TXNIP can function as a tumor 
suppressor mainly through regulating ERK activity, which is strongly associated with 
oncogenic process toward bladder carcinogenesis. Since the present study remains 
observational, the precise mechanism of action should be clarified in the next studies.  
Phosphorylation of ERK can occur via activation of either of several signal pathways 
including receptor tyrosine kinases (i.e., IGF-1R and EGFR) or 7TMRs (i.e., CXCR4). In the 
present study, BBN administration induced both CXCR4 expression in urothelial cells and 
SDF-1 expression in stromal mesenchyme cells. In contrast, bladder cancer cell lines 
transfected with TXNIP demonstrated attenuated CXCR4-ERK activation upon SDF-1 stimuli. 
Therefore, CXCR4 is considered to be a major up-stream receptor activating ERK signaling; 
it plays an important role in bladder carcinogenesis by stimulating several transcription 
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factors. Indeed, CXCR4 antagonist significantly attenuates ERK activation and suppresses 
bladder carcinogenesis in both WT and Txnip-KO mouse model, to almost the same level. 
Since the effects of TXNIP deletion is abrogated by CXCR4 antagonist, there seems to be a 
causal link between TXNIP deletion and enhanced bladder carcinogenesis. These results 
suggest that TXNIP suppression facilitates bladder carcinogenesis by enhancing 
CXCR4–ERK activation.  
Another important upstream regulator of ERK is the Ras signaling pathway, which is 
activated by receptor tyrosine kinases such as IGF-1R, EGFR and FGFR3. Aberrant activation 
of Ras oncoproteins is associated with development of low-grade non-muscle invasive 
bladder cancer (25). However, BBN-induced mouse bladder cancer shows a morphologic 
effect similar to another bladder carcinogenesis pathway, namely high-grade CIS 
muscle-invasive cancer pathway (25). In the present study, restoration of TXNIP did not alter 
ERK activation upon IGF-1 or EGF stimuli; and CXCR4 blockade suppressed BBN-induced 
carcinogenesis. Also, TXNIP expression is significantly more suppressed in high-grade 
muscle-invasive human bladder cancers than in low-grade non-muscle-invasive types of 
cancer. These findings suggest that activation of SDF-1-CXCR4 signaling drives a CIS 
muscle-invasive bladder cancer pathway, and that a major effect of TXNIP loss is to facilitate 
this pathway. Recent reports support the notion that the ERK pathway plays an important role 
in muscle invasive bladder cancer (26–29). Because TXNIP expression is also suppressed in 
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low-grade non-muscle-invasive bladder cancers compared to normal urothelia, loss of TXNIP 
may play other roles in bladder carcinogenesis, which should be elucidated in future studies.  
 Using a BBN-induced bladder carcinogenesis mouse model, we have shown that 
CXCR4 antagonist TF14016 can reduce bladder carcinogenesis. The 14-mer peptide T140 was 
developed from structure-activity relationship studies of two antibacterial and antiviral peptides; 
17-mer peptide tachyplesins and 18-mer peptide polyphemusins isolated from the Japanese 
horseshoe crab (Tachypleus tridentatus) and the American horseshoe crab (Limulus 
polyphemus), respectively. T140 possesses potent anti-HIV activity by binding specifically to 
CXCR4 and TF14016 is a potent and bio-stable T140 analog (20). To our knowledge, this is 
the first report of successful bladder cancer prevention using a drug that attenuates a specific 
oncogenic signal. A limitation of the present study is that the therapeutic effect of TF14016 on 
established bladder tumors have not been clarified. Therefore, it seems the most reasonable 
and practical to use this drug to prevent recurrence of high-grade bladder cancer after 
transurethral resection (TUR). Prevention of post-TUR bladder cancer recurrence is a major 
clinical challenge, although some anti-cancer drugs and Bacillus Calmette-Guérin (BCG) are 
currently available with partial effects. Although some newly developed antigen-based drugs 
and molecular-targeted agents have been tested for this purpose (30), none of these novel 
treatments has been established so far. Peptide-based TF14016 and its analogs also offer 
advantages in terms of cost over other novel treatment modalities. Although we did not find 
20 
any lethal reaction or significant weight loss during the 12 weeks’ treatment, further 
evaluation of acute and chronic adverse events is essential for the future clinical use. 
In conclusion, TXNIP, which is silenced during bladder carcinogenesis, suppresses ERK 
activation in the SDF-1-CXCR4 signaling and also bladder carcinogenesis, suggesting that 
SDF-1-CXCR4-ERK signaling might be a good target to prevent bladder cancer. 
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Fig. 1. Messenger RNA level of TXNIP gene is suppressed in bladder cancers. (A) Compared 
with normal urothelium, TXNIP is suppressed in human bladder cancers. Particularly in high 
grade and/or high stage (pT1 or more) cancers TXNIP is strongly suppressed. All bladder 
cancer cell lines express little if any TXNIP. (B, C) Txnip is suppressed in a BBN-induced 
bladder cancer model. Bladder carcinoma in situ (CIS) developed after 8–12 weeks of BBN 
administration in WT mice (B). (C) Sequential change of mRNA of Txnip in BBN-induced 
mouse bladder carcinogenesis. Txnip is suppressed at 4 weeks of BBN administration and 
declined time-dependently over the course of BBN administration; n = 3 in each group. 
Statistical analysis: Post-hoc test (Fisher’s PLSD). (D) Western blot for TXNIP in 
BBN-induced mouse bladder carcinogenesis. TXNIP is down-regulated at 8 weeks of BBN 
consumption and down-regulated over the course of BBN administration.  
Fig. 2. Txnip-KO mice develop BBN-induced bladder cancer earlier than WT mice. (A) 
Representative histologies of mouse bladder in WT mice (top) and Txnip-KO mice (bottom). 
H&E staining, original magnification  200 (NCT) and  100 (8 and 12 weeks). 
(B–D) Histograms showing ratio of bladder cancer according to duration of BBN treatment. 
Overlaid line indicates mean Txnip levels of WT mice at each time point relative to the 
baseline. (B) Overall cancers; (C) high grade cancer; (D) invasive cancer (pT1 or more) 
and/or SCC. (E) Representative immunohistochemistry for TXNIP in WT mouse bladder 
28 
cancer. TXNIP level in bladder urothelia was down-regulated in CIS at 12 weeks and T1 
cancer at 20 weeks of BBN treatment compared to baseline (0 week) in WT mice (Figures 
2D).  
Fig. 3. (A) Western blot for ERK, AKT, and JNK signaling. Phosphorylation levels of ERK, 
AKT, and JNK are up-regulated at 8 weeks of BBN consumption compared to baseline. 
pERK is more up-regulated in Txnip-KO mice than in WT mice at 8 weeks of BBN 
consumption. The chart below shows densitometric values for pERK, pAKT, and pJNK 
relative to the baseline. (B) Representative immunohistochemistry for pERK in Txnip-KO 
mouse bladder cancer. pERK are up-regulated in urothelial cells after 8 weeks of BBN 
administration. Original magnification  200. 
Fig. 4. (A) Forced expression of TXNIP attenuates pERK response to SDF-1 in human 
bladder cancer cell lines. The cell line 253J-HA-TXNIP-1 and 2 showed decreased activation 
of pERK after SDF-1 treatment compared with the control cells (arrowhead). Similar results 
were obtained from TCCSUP-HA-TXNIP. Densitometric values are shown in the chart below. 
(B) Timeframe analysis of pERK activation after SDF-1 treatment in FBS-free medium. 
Lower panel shows time-dependent changes in densitometric values for pERK. Similar results 
were obtained from TCCSUP-HA-TXNIP. (C) Forced expression of TXNIP did not influence 
major receptor tyrosine kinase pathways including EGFR and IGF-1R signaling. 
29 
Fig. 5. (A) Western blot for SDF-1, CXCR4 and ERK in BBN-induced bladder carcinogenesis 
of both WT and Txnip-KO mice. CXCR4 is induced at 2 weeks of BBN administration in 
both WT and Txnip-KO mice, whereas the SDF-1 level did not show obvious changes. On the 
other hand, pERK was more enhanced in Txnip-KO mice than in the WT mice. (B–D) A 
specific CXCR4 antagonist TF14016 suppressed BBN-induced ERK activation and bladder 
carcinogenesis in Txnip-KO mice. (B) TF14016 suppressed pERK after 12 weeks of BBN 
administration in both WT mice and Txnip-KO mice. (C) Representative histology of mouse 
bladder. TF14016 suppressed bladder carcinogenesis after 12 weeks of BBN administration in 
both WT mice and Txnip-KO mice. Original magnification  200. (D) TF14016 reduced the 
incidence of bladder carcinogenesis after 12 weeks of BBN administration in Txnip-KO mice 
to almost the same level as observed in WT mice. 
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Table 1. Patients’ characteristics of 39 bladder cancers and 6 normal urothelial samples 
including age, grade, sex, smoking habits, 5 year recurrence-free survival. Briskman’s index: 








and            
low stage
High grade 
and/ or       
high stage
Total
Patients (No.) 6 12 27 39
Age  [average (S.D.)] 67.5 (7.0) 66.3 (12.0) 72.7 (14.7) 70.7 (14.1)


























% Tobacco smoker 33 25 32 30
Briskman’s index 
[average (S.D.)] 
108 (208) 309 (807) 247 (683)
% 5yr recurrence-free 
survival
- 50 41* 44
Table 1
Human low grade and non-muscle invasive cancers (arrows).
Human high grade and muscle-invasive bladder cancers (arrows). 
A
B
Mouse bladders.    Arrows: urothelium or cancer.
Normal bladder CIS Invasive cancer
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